Predictive capability of sarcopenia in patients treated with immune checkpoint inhibitors. A meta-analysis
Not Applicable
- Conditions
- cancer patients treated with immune checkpoint inhibitors
- Registration Number
- JPRN-UMIN000042621
- Lead Sponsor
- Kansai medical hospital
- Brief Summary
A total of 2501 patients from 26 studies were analysed. Sarcopenia was observed in 44.7% of the patients and was significantly associated with poor survival.Poor radiological response to ICI therapy was observed in patients with sarcopenia.The occurrence of severe toxicity was not associated with sarcopenia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2501
Inclusion Criteria
Not provided
Exclusion Criteria
review, case report, animal study languages other than English or Japanese
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method hazard ratio for progression free survival hazard ratio for overall survival odds ratio for objective response odds ratio for disease control odds ratio for toxicity
- Secondary Outcome Measures
Name Time Method